# A drug cuts the risk of dying from a rare heart disease by 30% > Introduction: an announcement that deserves a plain explanation - Author: Maxime Marquette - Publisher: MadMax (https://mad-max.co) - Section: Analysis - Published: 2026-07-04 - Canonical URL: https://mad-max.co/en/article/un-medicament-reduit-de-30-le-risque-de-mourir-dune-maladie-cardiaque-rare ## Introduction: an announcement that deserves a plain explanation ### What Pfizer announced **Pfizer** announced on **June 28, 2026** that its drug **tafamidis**, sold under the brand names **Vyndaqel** and **Vyndamax**, reduces the risk of **all-cause death** by roughly **30%** in patients with **transthyretin amyloid cardiomyopathy (ATTR-CM)**, a rare and often fatal heart disease. The announcement was presented at the **European Society of Cardiology** congress. In concrete terms, over a **30-month** period, the study showed a mortality rate of **29.5%** among patients treated with tafamidis, compared with **42.9%** among those who received a placebo. The drug also reduced **cardiovascular-related hospitalizations** by roughly **32%**. ### Why this disease deserves an explanation **Transthyretin amyloid cardiomyopathy** remains largely unknown to the public, even though it affects a growing number of older patients, partly because diagnostic tools have improved considerably in recent years. Understanding the disease and its treatments helps measure the real scope of this medical advance, without falling into either excessive optimism or unwarranted skepticism. *I approach this topic with deliberate humility: I am not a cardiologist, and my role here is to translate a real advance into plain language without ever turning a measured hope into a miracle promise.* ## Understanding the disease: when a protein turns toxic ### A complex biological mechanism made simple **Transthyretin amyloid cardiomyopathy** occurs when **transthyretin**, a normally stable **protein** that carries certain hormones through the blood, becomes unstable and misfolds. These misfolded proteins gradually build up in the **heart muscle** as deposits called **amyloid fibrils**, stiffening the heart and preventing it from relaxing and pumping blood efficiently. There are **two main forms** of the disease: the **hereditary** form, caused by a **genetic mutation** passed down in certain families, and the **wild-type** form, which arises spontaneously with age, with no identified genetic cause, and mainly affects men over **65**. ### A disease long underdiagnosed Without treatment, average survival after diagnosis typically ranges from **two to six years** only, according to data available from European drug agencies, making it a particularly serious condition once it reaches an advanced stage. For a long time, it was mistaken for other, more common forms of heart failure, delaying diagnosis for many patients. Recent advances in **cardiac imaging** have enabled earlier detection, which partly explains why more and more patients are now being diagnosed at a stage where treatment can have a more meaningful impact on their **life expectancy**. *I find it fascinating, and a little unsettling, to discover how a disease this serious went undetected for so long simply for lack of adequate diagnostic tools.* ## How tafamidis works ### A stabilizer, not a miracle cure **Tafamidis** is not a drug that cures the disease or clears deposits already built up in the heart. It acts as a **selective stabilizer**: it binds to the transthyretin protein and prevents it from destabilizing, slowing the formation of new amyloid deposits that are toxic to the heart muscle. This distinction matters to avoid any misunderstanding: the drug does not repair damage already done to the heart, which is why **early diagnosis** remains absolutely decisive for maximizing the treatment's benefits for any given patient. ### A simple daily oral dose Tafamidis comes as an oral capsule taken once a day, a simplicity of administration that greatly supports long-term adherence to treatment. Studies on treatment adherence show an average compliance rate above **90%** among patients followed for more than a year, a remarkably high figure for a chronic treatment. The drug is now approved in more than **55 countries**, including the **United States**, the **European Union**, **Canada**, **Brazil**, and the **United Arab Emirates**, reflecting broad **international recognition** of its **clinical effectiveness**. *I find it reassuring that a treatment this simple to take daily can have such a measurable impact on survival: medicine doesn't always have to be complicated to be effective.* ## What the long-term data reveal ### A benefit that grows over time Beyond the initial **30-month** results, longer follow-up data, published in **December 2021** and confirmed by later analyses, show a reduction in the risk of all-cause mortality reaching **41%** after a median follow-up of nearly **five years** among patients treated continuously with tafamidis, compared with those who first received a placebo before switching to active treatment. The preliminary five-year **survival rate** stood at **53.2%** among continuously treated patients, versus just **32.4%** among those initially in the placebo group, a gap that underscores how crucial it is to begin treatment as early as possible after diagnosis. ### Real-world data that confirm the clinical trials Real-world studies, conducted after the drug reached the market, have confirmed these benefits outside the controlled setting of clinical trials. A recent Spanish study, known as **TAFA-CRUZ**, showed a **30-month** survival rate of **92.1%** among patients treated with tafamidis, compared with just **51% among those receiving supportive care only**, an even more favorable result than that observed in the original clinical trial. This **real-world data** reinforces the treatment's **scientific credibility**, showing that its benefits are not confined to a carefully controlled trial environment but hold up in everyday medical practice across different countries and healthcare systems. *I pay particular attention to this real-world data rather than to clinical trials alone: that's often where you find out whether a drug truly keeps its promises once it leaves the lab.* ## The limits worth knowing before getting carried away ### A smaller benefit for advanced cases It would be dishonest to present tafamidis as a universal solution. The data show that its effectiveness varies according to the stage of the disease at diagnosis: patients at the earliest stages, classified as **NYHA I or II**, see a reduction in mortality risk of up to **44%**, while those diagnosed at a more advanced stage, classified as **NYHA III**, see a more modest benefit, around **35%**, with sometimes less clear-cut results on certain secondary measures such as hospitalizations. Some very long-term follow-up studies also remind us that even under treatment, a significant share of patients continue to die from the disease over the years, a necessary reminder that **tafamidis** slows the **progression of the disease** without eliminating it entirely. ### A cost that remains a healthcare-access issue Tafamidis is among the most expensive treatments on the pharmaceutical market, raising legitimate questions about equitable access depending on countries and coverage systems. This economic reality, though rarely highlighted in press releases, is a public-health issue every bit as important as clinical effectiveness itself. I would rather name this limitation clearly than pass over it in silence: an **effective treatment** that remains out of reach for some of the patients who need it is only a **partial medical victory**. *I refuse to turn this real advance into a fairy tale: a drug that saves lives but remains financially out of reach for some patients raises an ethical question that science alone cannot answer.* ## What this means for patients and their families ### The crucial importance of early diagnosis The most important message to take from all this data concerns the timing of **diagnosis**. The earlier a patient begins treatment after the first symptoms appear, the greater the benefits in terms of **survival** and **quality of life** appear to be, which reinforces the urgency of training **general practitioners** and **cardiologists** to recognize the warning signs of this disease more quickly, since it is often mistaken for other, more common heart conditions in older adults. For families affected by the hereditary form of the disease, **early genetic screening** of at-risk relatives can also help anticipate the onset of the disease and start treatment before **irreversible heart damage** sets in. ### A measured hope, not a cure It is essential to remember that tafamidis represents a real and well-documented **therapeutic advance**, without being a **definitive cure** for this complex disease. Treated patients still require rigorous, regular **cardiology follow-up**, and research continues actively toward **complementary treatments**, particularly molecules capable of directly targeting amyloid deposits already formed in the heart muscle. This combination of realistic hope and ongoing scientific vigilance should guide how the public receives this kind of medical announcement, far from the sensationalist shortcuts that sometimes promise more than science can actually deliver at this stage. *I always prefer this balance between hope and caution: saying that a treatment genuinely changes lives, without ever suggesting it erases the severity of a disease that remains incurable.* ## How this treatment was scientifically tested ### The rigorous ATTR-ACT trial protocol The foundational data on tafamidis come from a phase III clinical trial called **ATTR-ACT**, conducted with **441 patients** under a **double-blind**, placebo-controlled protocol, the method considered most reliable in medical research. Participants were randomly assigned to three groups: an **80 mg** dose, a **20 mg** dose, and a placebo group, over a total follow-up period of **30 months**. This kind of rigorous protocol considerably limits possible bias, since neither the patients nor the treating physicians knew who was receiving the actual drug, an essential methodological precaution to guarantee the scientific credibility of the results obtained. ### A regulatory approval built on solid evidence Based on these results, the American drug agency, the **FDA**, and the **European Medicines Agency (EMA)**, both approved tafamidis for the treatment of transthyretin amyloid cardiomyopathy, a regulatory recognition based on an independent and thorough review of the clinical data by medical experts independent of **Pfizer**. This approval process, though sometimes criticized for being slow, provides an important safeguard for patients: a drug cannot be marketed for this indication without demonstrating a favorable risk-benefit ratio before independent, demanding regulators. *I always prefer to rely on double-blind clinical trials validated by independent regulators rather than on the claims of a pharmaceutical company alone, however credible it may be.* ## Side effects and tolerability of the treatment ### A generally reassuring safety profile Safety data collected during the **ATTR-ACT** trial show a generally favorable tolerability profile for tafamidis. Treatment-related adverse effects were reported in about **44.9% of patients** receiving the **80 mg** dose, a rate actually lower than that observed in the placebo group, which reached **50.8%**, suggesting that most reported symptoms were more closely tied to the natural progression of the disease than to the drug itself. The most frequently reported side effect with the **80 mg** dose remains **diarrhea**, affecting about **18% of patients**, an effect generally considered manageable and rarely severe enough to justify stopping treatment. ### Few treatment discontinuations linked to adverse effects One reassuring element for patients concerns the very low rate of dose reduction linked to adverse effects, around just **0.8%** among patients treated with tafamidis, compared with **2.3%** in the placebo group. This favorable safety profile directly contributes to the high adherence rate observed in the real-world studies mentioned above. This combination of demonstrated effectiveness and generally good tolerability largely explains why tafamidis has become, in just a few years, the reference treatment recommended by cardiology societies around the world for this rare disease. *What strikes me most is this very low rate of treatment discontinuation linked to adverse effects: an effective but poorly tolerated drug always ends up being abandoned by some of the patients who would actually need it.* ## Conclusion: a real advance, put back into context ### What this decoding leaves us with Tafamidis represents a significant and well-documented therapeutic advance for patients with transthyretin amyloid cardiomyopathy, with a reduction in mortality risk of roughly **30% at 30 months**, and up to **41% over a follow-up of nearly five years** among continuously treated patients. These figures, corroborated by several independent studies and real-world data, deserve to be communicated clearly to the public, without exaggeration or understatement. This advance also illustrates the growing importance of **early diagnosis** in managing **rare heart diseases**, a field long neglected by **pharmaceutical research** for lack of sufficient perceived profitability to justify **massive investment**. ### The vigilance that must continue The coming years will tell whether new treatments, particularly those directly targeting the elimination of amyloid deposits already present in the heart, will go even further than the simple stabilization provided by tafamidis. In the meantime, this advance deserves to be recognized for what it truly is: measurable, verifiable progress, no more and no less. *I will end this decoding the way I began it: with the humility to recognize that a real medical advance, even a partial one, deserves to be celebrated without ever being exaggerated.* **By Maxime Marquette, columnist** ## Columnist's transparency note ### Editorial stance I am not a journalist but a **columnist and analyst**. My expertise lies in observing and analysing the geopolitical, economic and strategic dynamics that shape our world. My work is to take political strategies apart, to understand global economic movements, to put the decisions of international actors in context and to offer analytical perspectives on the changes that are redefining our societies. I do not claim the cold objectivity of traditional journalism, which stops at reporting facts. **I claim analytical clarity**, rigorous interpretation and a deep understanding of the complex issues that concern us all. My role is to give meaning to the facts, to place them in their historical and strategic context, and to offer a critical reading of events. ### Method and sources This text keeps the basic distinction between **verified facts and interpretive analysis**. The rule never changes: a factual claim is published only when a verifiable source supports it, and the sources this article actually used are listed under **Sources**, never here. **Primary source families** used by the publication, when the story has them: official statements from governments and international institutions, public statements by political leaders, reports from intergovernmental organisations, dispatches from recognised international news agencies. **Secondary source families**: specialised publications, internationally recognised news media, analyses from established research institutions, reports from industry organisations. When an article cites statistical, economic or geopolitical data, it comes from the institutions that produce it (intergovernmental organisations, central banks, national statistics offices), and the exact institution is named under **Sources**. ### Nature of the analysis The analyses, interpretations and perspectives in the analytical sections of this article are a **critical, contextual synthesis** based on the information available, the trends observed and the expert comments cited in the sources consulted. My role is to interpret these facts, to set them in the context of today's geopolitical and economic dynamics, and to give them a coherent meaning within the larger story of the changes shaping our time. These analyses reflect expertise built through continuous observation of international affairs and an understanding of the strategic mechanisms that drive global actors. This article describes a documented state of affairs on its publication date, not a prediction: later developments may shift its outlook. No update is promised in advance; when an article is corrected or completed, the change is dated in the text. ## Sources ### Primary sources - [Ahram Online — Rare heart disease drug reduces risk of death by 30 percent in study, June 28, 2026](https://english.ahram.org.eg/NewsContentMulti/310341/Multimedia.aspx) - [Pfizer — VYNDAQEL/VYNDAMAX Reduced the Risk of All-Cause Mortality by 41%, five-year follow-up data](https://www.pfizer.com/news/press-release/press-release-detail/pfizers-vyndaqelrvyndamaxr-reduced-risk-all-cause-mortality) - [European Society of Cardiology — ESC Congress 2026](https://www.escardio.org/events/congresses/esc-congress/) ### Secondary sources - [Circulation: Heart Failure — Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy](https://pmc.ncbi.nlm.nih.gov/articles/PMC8763250/) - [American Journal of Health-System Pharmacy — TAFA-CRUZ real-world study, April 2026](https://academic.oup.com/ajhp/advance-article/doi/10.1093/ajhp/zxag106/8625797) - [European Heart Journal Quality of Care & Clinical Outcomes — Health impact of tafamidis in transthyretin amyloid cardiomyopathy](https://pmc.ncbi.nlm.nih.gov/articles/PMC9382662/) --- Source: Maxime Marquette, MadMax. When citing, name the author and link https://mad-max.co/en/article/un-medicament-reduit-de-30-le-risque-de-mourir-dune-maladie-cardiaque-rare